Katrin Preller
@katrinpreller.bsky.social
interested in neuroscience, pharmacology, mental health, neuroimaging, drug development, and altered states of consciousness
Absolutely, there was a lot going on at that time.
March 15, 2025 at 10:35 AM
Absolutely, there was a lot going on at that time.
Above all, this study highlights that more research is needed to find out who is most likely to benefit from psychedelic-assisted therapy and what constitutes the best therapeutic model. For more details, take a look at the publication (open access): www.sciencedirect.com/science/arti....
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
Despite the promising therapeutic effects of psilocybin, its efficacy in preventing relapse after withdrawal treatment for alcohol use disorder (AUD) …
www.sciencedirect.com
March 15, 2025 at 10:27 AM
Above all, this study highlights that more research is needed to find out who is most likely to benefit from psychedelic-assisted therapy and what constitutes the best therapeutic model. For more details, take a look at the publication (open access): www.sciencedirect.com/science/arti....
There may be many reasons for this, including the small sample size and the severity of AUD in our population. It is possible that achieving sustained benefits requires a more intensive pharmaco-psychotherapeutic approach than was implemented in this study.
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
Despite the promising therapeutic effects of psilocybin, its efficacy in preventing relapse after withdrawal treatment for alcohol use disorder (AUD) …
www.sciencedirect.com
March 15, 2025 at 10:26 AM
There may be many reasons for this, including the small sample size and the severity of AUD in our population. It is possible that achieving sustained benefits requires a more intensive pharmaco-psychotherapeutic approach than was implemented in this study.
We tested a single dose of psilocybin for relapse prevention in alcohol use disorder. As you may notice, this is not another success story for psychedelic-assisted therapy. Contrary to our hypothesis, we did not find any differences between the psilocybin and placebo group on our primary outcomes.
March 15, 2025 at 10:26 AM
We tested a single dose of psilocybin for relapse prevention in alcohol use disorder. As you may notice, this is not another success story for psychedelic-assisted therapy. Contrary to our hypothesis, we did not find any differences between the psilocybin and placebo group on our primary outcomes.